The main objectives of the study were

• to compare the pharmacokinetics (PK) of Optivate® and Haemate P® in various types of vonWillebrand disease (VWD) using the results from the VWF: RCo, VWF:Ag, VWF:CBA and Factor VIII assays.
• to compare the clinical tolerance and safety of these two treatments after single IV infusions in subjects with VWD.

Inclusion Criteria:

• Previously treated subjects of at least 12 years of age, with any type of VWD were eligible for entry into this study.

Exclusion Criteria:

-